Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer

British Journal of Cancer

Volumn 102, Issue 9, 2010, Pages 1391-1396

  Wong, H ^a   Lau, S ^b   Yau, T ^a   Cheung, P ^b   Epstein, R J ^a,b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

Breast neoplasms; Carcinogenesis; Intraductal; Ki 67; Pre invasive; Tumour progression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POSTMENOPAUSE; PREMENOPAUSE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; SURVIVORS;

EID: 77951668699     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605655     Document Type: Article

References (32)

1. Alexe G, Dalgin GS, Ganesan S, Delisi C, Bhanot G (2007) Analysis of breast cancer progression using principal component analysis and clustering. J Biosci 32: 1027-1039
2. Allred DC, Mohsin SK, Fuqua SA (2001) Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8: 47-61
3. Aubele M, Mattis A, Zitzelsberger H, Walch A, Kremer M, Welzl G, Hofler H, Werner M (2000) Extensive ductal carcinoma in situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. Int J Cancer 85: 82-86
4. Barnard NJ, Hall PA, Lemoine NR, Kadar N (1987) Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol 152: 287-295
5. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JF, Blamey RW, Nicholson RI (1989) Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59: 943-947
6. Buerger H, Mommers EC, Littmann R, Simon R, Diallo R, Poremba C, Dockhom-Dwomiczak B, van Diest PJ, Boecker W (2001) Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 194: 165-170
7. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM (2004) Ductal carcinoma in situ of the breast. N Engl J Med 350: 1430-1441
8. Castro NP, Osorio C, Torres C, Bastos EP, Mourão-Neto M, Soares FA, Brentani HP, Carraro DM (2008) Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 10: R87
9. Chagpar AB, McMasters KM, Sahoo S, Edwards MJ (2009) Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis? Surgery 146: 561-567
10. Epstein RJ (2009) TNM: therapeutically not mandatory. Eur J Cancer 45: 1111-1116
11. Farabegoli F, Champeme M, Bieche I, Santini D, Ceccarelli C, Derenzini M, Lidereau R (2002) Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 196: 280-286
12. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 966-978
13. Gao Y, Niu Y, Wang X, Wei L, Lu S (2009) Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization. J Mol Med 87: 145-152
14. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD (1991) Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867-873
15. Golubovskaya VM, Conway-Dorsey K, Edmiston SN, Tse C, Lark AA, Livasy CA, Moore D, Millikan RC, Cance WG (2009) FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer 125: 1735-1738
16. Iakovlev V, Arneson N, Wong V, Wang C, Leung S, Iokovleva G, Warren K, Pintilie M, Done S (2008) Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study. Clin Cancer Res 14: 4446-4454
17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249
18. Jung SY, Han W, Lee JW, Ko E, Kim E, Yu JH, Moon HG, Park IA, Oh DY, Im SA, Kin TY, Hwang KT, Kin SW, Noh DY (2009) Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Onlin risk categories in early breast cancer. Ann Surg Oncol 16: 1112-1121
19. Lightfoot HMJ, Lark A, Livasy CA, Moore DT, Cowan D, Dressler L, Craven RJ, Cance WG (2004) Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. Breast Cancer Res Treat 88: 109-116
20. Locker AP, Birrell K, Bell JA, Nicholson RI, Elston CW, Blamey RW, Ellis IO (1992) Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol 18: 224-229
21. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, Schechter CB, Sigal B, Stoto MA, Stout NK, van Ravesteyn NT, Venier J, Zelen M, Feuer EJ, for the Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network (CISNET) (2009) Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 151: 738-747
22. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B (2005) Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res 25: 1719-1723
23. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L (2009) Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 151: 727-737
24. Patla A, Rudnicka-Sosin L, Pawlega J, Stachura J (2002) Prognostic significance of selected immunohistochemical parameters in patients with invasive breast carcinoma concomitant with ductal carcinoma in situ. Pol J Pathol 53: 25-27
25. Pinder SE, Ellis IO (2003) The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)-definitions and classification. Breast Cancer Res 5: 254-257
26. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, Fehm T, Solomayer E, Riess O, Wallwiener D, Kurek R, Neubauer HJ (2006) Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 66: 5278-5286
27. Shaaban AM, Sloanne JP, West CR, Foster CS (2002) Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol 160: 597-604
28. Simpson PT, Da Silva LM, Lakhani SR (2007) In situ carcinoma-can we predict which patient will come back with a recurrence? Cancer Cell 12: 409-411
29. Steinman S, Wang J, Bourne P, Yang Q, Tang P (2007) Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci 37: 127-134
30. Tanaka T (2009) Colorectal carcinogenesis: review of human and experimental animal studies. J Carcinog 8: 5
31. van Steenbergen LN, Voogd AC, Roukema JA, Louwman WJ, Duijm LE, Coebergh JW, van de Poll-Franse LV (2009) Screening caused rising incidence rates of ductal carcinoma in situ of the breast. Breast Cancer Res Treat 115: 181-183
32. Wu M, Jung L, Cooper AB, Fleet C, Chen L, Breault L, Clark K, Cai Z, Vincent S, Bottega S, Shen Q, Richardson A, Bosenburg M, Naber SP, DePinho RA, Kuperwasser C, Robinson MO (2009) Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. Proc Natl Acad Sci USA 106: 7022-7027